| Dr Ayesha N Zaheer, MD | |
|
4647 Medical Dr, San Antonio, TX 78229-4403 | |
| (210) 358-5510 | |
| (210) 358-8536 |
| Full Name | Dr Ayesha N Zaheer |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 26 Years |
| Location | 4647 Medical Dr, San Antonio, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184804973 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | N4221 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Health System | San antonio, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Community Medicine Associates | 7719979509 | 385 |
News Archive
These reports have emerged from a Daily Telegraph investigation. Australian Medical Association vice president, GP and former Pharmaceutical Benefits Advisory Committee member Dr Steve Hambleton said the resons for these trends may include the increasing population of the aged, newer medicines as well as a rise in chronic lifestyle ailments like diabetes and high blood pressure.
The introduction of thousands of Ebola treatment beds by the UK and Sierra Leone governments and NGOs prevented an estimated 57,000 Ebola cases and 40,000 deaths in Sierra Leone, according to new research published in the Proceedings of the National Academy of Sciences.
ArQule, Inc. today announced the presentation of final results from a Phase 2 clinical trial in non-small cell lung cancer (NSCLC) of ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, at the annual meeting of the European Society for Medical Oncology (ESMO).
Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the research and development of novel drug candidates based on proprietary macrocyclic chemistry, today announced the signing of a discovery and co-development agreement with Southern Research Institute, a not-for-profit 501(c)(3) scientific research organization founded in 1941.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that it has submitted a Supplemental New Drug Application with the U.S. Food and Drug Administration seeking approval for the marketing and sale of Lymphoseek (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer, an indication for which Lymphoseek was also granted Fast Track designation earlier this month.
› Verified 5 days ago
| Entity Name | Community Medicine Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245313329 PECOS PAC ID: 7719979509 Enrollment ID: O20040401000372 |
News Archive
These reports have emerged from a Daily Telegraph investigation. Australian Medical Association vice president, GP and former Pharmaceutical Benefits Advisory Committee member Dr Steve Hambleton said the resons for these trends may include the increasing population of the aged, newer medicines as well as a rise in chronic lifestyle ailments like diabetes and high blood pressure.
The introduction of thousands of Ebola treatment beds by the UK and Sierra Leone governments and NGOs prevented an estimated 57,000 Ebola cases and 40,000 deaths in Sierra Leone, according to new research published in the Proceedings of the National Academy of Sciences.
ArQule, Inc. today announced the presentation of final results from a Phase 2 clinical trial in non-small cell lung cancer (NSCLC) of ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, at the annual meeting of the European Society for Medical Oncology (ESMO).
Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the research and development of novel drug candidates based on proprietary macrocyclic chemistry, today announced the signing of a discovery and co-development agreement with Southern Research Institute, a not-for-profit 501(c)(3) scientific research organization founded in 1941.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that it has submitted a Supplemental New Drug Application with the U.S. Food and Drug Administration seeking approval for the marketing and sale of Lymphoseek (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer, an indication for which Lymphoseek was also granted Fast Track designation earlier this month.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ayesha N Zaheer, MD Po Box 734812, Dallas, TX 75373-4812 Ph: (210) 358-9500 | Dr Ayesha N Zaheer, MD 4647 Medical Dr, San Antonio, TX 78229-4403 Ph: (210) 358-5510 |
News Archive
These reports have emerged from a Daily Telegraph investigation. Australian Medical Association vice president, GP and former Pharmaceutical Benefits Advisory Committee member Dr Steve Hambleton said the resons for these trends may include the increasing population of the aged, newer medicines as well as a rise in chronic lifestyle ailments like diabetes and high blood pressure.
The introduction of thousands of Ebola treatment beds by the UK and Sierra Leone governments and NGOs prevented an estimated 57,000 Ebola cases and 40,000 deaths in Sierra Leone, according to new research published in the Proceedings of the National Academy of Sciences.
ArQule, Inc. today announced the presentation of final results from a Phase 2 clinical trial in non-small cell lung cancer (NSCLC) of ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, at the annual meeting of the European Society for Medical Oncology (ESMO).
Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the research and development of novel drug candidates based on proprietary macrocyclic chemistry, today announced the signing of a discovery and co-development agreement with Southern Research Institute, a not-for-profit 501(c)(3) scientific research organization founded in 1941.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that it has submitted a Supplemental New Drug Application with the U.S. Food and Drug Administration seeking approval for the marketing and sale of Lymphoseek (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer, an indication for which Lymphoseek was also granted Fast Track designation earlier this month.
› Verified 5 days ago
Dr. Obinna C. Uzowulu, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 22250 Bulverde Rd, Suite 111, San Antonio, TX 78261 Phone: 210-899-4490 Fax: 210-592-8195 | |
Dr. Salima Jaffer, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 22800 Bulverde Rd Apt 2202, San Antonio, TX 78261 Phone: 210-878-4033 | |
David A. Ramos, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3110 Nogalitos, Suite 105, San Antonio, TX 78225 Phone: 210-533-0257 Fax: 210-534-0890 | |
Patricia May B. Lacsina, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 903 W Martin St, San Antonio, TX 78207 Phone: 210-358-3441 Fax: 210-358-5944 | |
Adriana S Sanchez, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8300 Floyd Curl Dr, San Antonio, TX 78229 Phone: 210-450-9000 | |
Dr. Aneela N. Hussain, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 4610 E Southcross Blvd, San Antonio, TX 78222 Phone: 210-648-1491 | |
Javier C Bocanegra, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1616 Callaghan Rd, San Antonio, TX 78228 Phone: 210-435-1218 Fax: 210-435-3162 |